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Abstract
Triple-negative breast cancer (TNBC) has been recently recognized as an important subgroup of
breast cancer with a distinct outcome and therapeutic approach compared with other breast cancer
subgroups. Because TNBC is defined by the absence of a target (either hormone receptors or
HER-2), conventional cytotoxic therapy is still the mainstay of treatment. This report focuses on the
current state and recent advances in managing TNBC.
Introduction and context
Triple-negative breast cancer (TNBC) is defined by a lack
of expression of estrogen and progesterone receptors and
HER-2 as evaluated by immunohistochemistry methods.
This subgroup accounts for about 15% of all types of
breast cancers. Histologically, these tumors are poorly
differentiated and express cytokeratins 5/6 and 17.
Additional biological characteristics of this subtype are
epidermal growth factor receptor (EGFR) and c-KIT
overexpression in 57% and 31% of cases, respectively
[1]. Genomic expression profiling of this disease subtype
has associated it with basal cells of the mammary
epithelium (basal-like subtype) [2]. The basal-like breast
cancer subtype expresses a highly angiogenic phenotype,
includes many BRCA1-mutated tumors and has a poor
prognosis [2,3]. Furthermore, an earlier age of onset, a
high rate of local relapse, a higher incidence of visceral
metastases, and a high rate of cerebral metastases have
been reported in patients with basal-like breast cancer
[4,5]. The basal-like subtype is assigned by gene
expression profiling whereas the definition of TNBC is
based on immunohistochemical characteristics. More-
over, it is crucial to note that although most basal-like
cancers are triple negative, there is a moderate dis-
cordance between TNBC and basal-like breast cancer.
Although most basal-like cancers do not express estrogen
and progesterone receptors and HER-2, a small number
do and, therefore, the overlap between basal-like breast
cancer and TNBC is not complete and the terms are not
completely synonymous. Because of this discordance
and potential misclassification, in this review we refer to
basal-like breast cancer when a gene expression array was
used for characterization and to the TNBC subtype when
the analysis was limited to immunohistochemistry.
Preclinical studies on BRCA1-related breast cancers have
shown high sensitivity to alkylating agents, mitomycin-
C, and platinum compounds as well as sensitivity to
agents inducing DNA double-strand breaks such as
etoposide and bleomycin, but resistance to mitotic-
spindle poisons such as taxanes and vinca alkaloids has
been recorded [6]. Multiple data have consistently
identified a poorer clinical outcome for women with
basal-like breast cancer, although modern regimens of
chemotherapy can alter the history of the disease [7].
The risk of recurrence is higher in the first 3–5 years,
suggesting that a substantial number of women are cured
if they remain disease-free for several years after
diagnosis [8,9]. A retrospective analysis of the Cancer
and Leukemia Group B (CALGB) 9344 trial found that
patients with either TNBC or HER-2-positive breast
cancer achieved the greatest benefit from the addition
of paclitaxel to doxorubicin and cyclophosphamide [10].
Similarly, dose-dense therapy seems to have the greatest
incremental benefit in women with estrogen receptor-
positive tumors [11]. Pathological and molecular deter-
minants of the chemosensitivity of breast cancers have
been extensively explored through neoadjuvant trials.
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features inherent to basal-like cancers, have been
consistently shown to be associated with clinical and
pathological responsiveness to neoadjuvant chemother-
apy [12,13]. In the neoadjuvant setting, basal-like breast
cancer has been associated with a significantly higher rate
of pathological complete response; however, relapse-free
and overall survival were very short [14-16]. On the
basis of limited clinical data, the TNBC subtype is
probably the most chemosensitive subtype of breast
cancer, although it is unclear which agents induce the
best response rate. From a biological stand point, DNA-
damaging agents, such as platinating agents, are very
high priority candidate agents based on the BRCA1 and
DNA repair dysfunction described in TNBC. Two studies
of neoadjuvant single agent cisplatin in women with
TNBC and women with both BRCA1 mutations and
TNBC have reported pathological complete response in
23% and 72% of cases, respectively [17,18]. These results
further support research into the utility of platinum
compounds in TNBC.
Recent advances
Several new drugs, including anti-angiogenic agents,
EGFR inhibitors, poly(ADP-ribose) polymerase (PARP)
inhibitors and Src kinase inhibitors, are currently under
investigation for use in metastatic TNBC.
Based on EGFR expression in gene profiling studies and
the dependence of basal-like breast cancer cell lines on
EGFR for growth and proliferation, several groups have
examined EGFR-targeting agents in TNBC. The TBCRC
(Translational Breast Cancer Research Consortium) 001
trialwasarandomizedtrialofcarboplatinincombination
with cetuximab versus cetuximab alone in patients with
metastatic TNBC. A crossover to carboplatin at progres-
sion was planned. The response rate to the combination
was 17%, with a clinical benefit seen in 29% of patients
[19].Asimilarstudyofirinotecanpluscarboplatinwithor
without cetuximab in metastatic breast cancer suggested,
on subset analysis, a modest higher response rate (30%
versus 40%) for the patients with TNBC receiving
cetuximab [20]. The role of anti-angiogenic therapy in
TNBC has been evaluated retrospectively on a subset
analysis in the ECOG (Eastern Cooperative Oncology
Group) 2100 trial. The trial randomized patients with
metastaticdiseasetoreceivepalitaxelplusbevacizumabor
paclitaxel alone as the first line of treatment. There was a
significant improvement of progression-free survival with
the addition of bevacizumab, including in the subgroup
of patients with largely TNBC [21]. A prospective trial of
neoajuvantcisplatinplusbevacizumabinTNBCshoweda
pathological response (Miller-Payne grade 4-5) of 36%.
[22]. Additional benefits from combining carboplatin
and paclitaxel and the addition of bevacizumab to
paclitaxel in TNBC will be directly studied in the
neoadjuvant trial CALGB 40603, which has a 2 × 2
randomized bi-factorial design.
Other novel agents of interest include the multitarget Src
kinase inhibitor dasatinib. A preclinical in vitro model of
sensitivity of dasatinib applied to expression profiles
from human tumors overlapped significantly with TNBC
tumors, suggesting promising activity [23]. However,
data from a phase II trial showed it had modest activity
as a single agent [24]. PARPs are molecules integrally
involved in nonhomologous DNA repair that become
the primary means of double-strand DNA repair when
the preferred homologous recombinant mechanism is
lost, as occurs when the BRCA1 pathway is defective.
BRCA1 loss or inactivation thus sensitizes cells to PARP
inhibitors [25]. Dysfunction of BRCA1 pathways is
present in hereditary breast cancer and in some TNBC
cases. Recently, data from two phase II clinical trials of
PARP inhibitors have been presented. Olaparib is an oral
PARP inhibitor and, as a single agent, showed substantial
activity in heavily pretreated BRCA1/BRCA2 carriers
with advanced breast cancer: the overall response rate
was 41% and the median progression-free survival was
5.7 months [26]. O’Shaughnessy et al. [27] presented
data from a phase II randomized trial of carboplatin plus
gemcitabine with or without BSI-201, a small-molecule
PARP inhibitor, in patients with metastatic TNBC. The
experimental regimen including BSI-201 showed a
significantly improved re s p o n s er a t e( 4 8 %v e r s u s
16%), clinical benefit rate (62% versus 21%), median
progression-free survival (6.9 versus 3.3 months) and
median overall survival (9.2 versus 5.7 months) [27].
Implications for clinical practice
In the adjuvant and curative setting, TNBC should be
treated with conventional therapies at this time. Despite
promising data from preclinical models and early phase
clinical trials, incorporation of platinum compounds or
other novel therapies should await further confirmation
from phase III clinical trials. Retrospective correlative
strategies focusing on the TNBC subgroup may help to
identify which patients will benefit most from standard
drugs. The recent advances should not change clinical
practice at this time. However, patients with TNBC
should be offered clinical trials looking at the efficacy
and safety of new drugs. Results from ongoing clinical
trials will soon provide information to enable us to
change therapeutic approaches to TNBC.
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